Imagine if you could find out if you need a colonoscopy just with a simple blood test instead of an invasive procedure. This project identifies specific proteins in the blood that act like red flags for cancer. It then uses AI to combine those flags with your lifestyle habits to tell you if you're actually at risk.
Low participation in colorectal cancer screening due to the invasive nature of colonoscopies. This leads to missed early detection opportunities, especially as the disease appears at younger ages.
A front-line screening tool combining protein biomarkers and risk factors, an AI assessment system, and a mobile application for behavioral change. A clinical study protocol for prospective studies was also developed.
If you are a blood testing laboratory dealing with low patient uptake for cancer screening — this project developed a protein biomarker blood test that identifies high-risk individuals. This allows you to offer a less invasive first-line screening tool to attract more patients.
If you are a health app developer dealing with low user engagement in preventative care — this project developed a mobile application that promotes personalized behavioral change based on modifiable risk factors. This provides a concrete tool to improve user health outcomes.
If you are a private clinic network dealing with inefficient colonoscopy scheduling — this project developed a screening tool that filters out healthy citizens. This ensures your colonoscopy resources are used only for those in definite need.
Based on available project data, the specific cost or price of the blood test and AI tool is not mentioned.
The project involves 17 industry partners and 13 SMEs, suggesting a strong focus on industrial scalability and commercial viability.
Based on available project data, specific details regarding patents or licensing agreements are not provided.
The tool acts as a front-line screen using standard bloodwork to identify who needs a colonoscopy, effectively filtering the patient pipeline.
The project period runs from 2023-01-01 to 2026-12-31, indicating the development phase concludes at the end of 2026.
The consortium is heavily weighted toward commercialization, with a 57% industry ratio consisting of 17 industry partners, including 13 SMEs. With 30 partners across 16 countries, the project has a broad European footprint, combining the academic rigor of 4 universities and 4 research institutes with significant private sector involvement to ensure the resulting blood test and app are market-ready.
Contact the EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTON in Greece.
Contact us to explore licensing opportunities for the AI biomarker detection tool.
